[Progress in targeting therapy for hepatic cancer].
Targeting therapy for hepatic cancer is divided into a method using Lipiodol as drug carrier and a method employing immunological responses of monoclonal antibodies to the tumor antigens. For the latter method, immuno-conjugates of antibodies and cytotoxic agents have been studied. Because of the lower response rates of conventional chemotherapy. Lipiodol as drug carrier provides the most effective targeting therapy on hepatic cancer at the present time. Immunotherapy using cytotoxic cells, however, did not result in sufficient clinical efficacy on the liver cancer. The system for accumulation of the effective and sufficient number of cytotoxic cells or immunoconjugates in the targeting tumor tissues are expected to be investigated.
Uchino
J
J
First Dept. of Surgery, Hokkaido University School of Medicine.
Une
Y
Y
Kamiya
T
T
Kawata
A
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016461:Chemoembolization, Therapeutic; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation; D008863:Microspheres; D013213:Starch / Q000008:administration & dosage; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000922:Immunotoxins; D007459:Iodized Oil; D013213:Starch